Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
2.080
+0.260 (14.29%)
At close: Apr 14, 2026, 4:00 PM EDT
2.080
0.00 (0.00%)
Pre-market: Apr 15, 2026, 4:17 AM EDT

Actuate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
12.26.483.273.82
Research & Development
10.2918.6821.7116.39
Total Operating Expenses
22.525.1624.9720.21
Operating Income
-22.5-25.16-24.97-20.21
Interest Income
0.290.220.350.03
Interest Expense
-0.02-0.02-0.04-0.02
Other Non-Operating Income (Expense)
--2.33-0.080.04
Total Non-Operating Income (Expense)
0.27-2.120.230.05
Pretax Income
-22.23-27.29-24.74-20.16
Net Income
-22.23-27.29-24.74-20.16
Net Income to Common
-22.23-27.29-24.74-20.16
Shares Outstanding (Basic)
21811
Shares Outstanding (Diluted)
21811
Shares Change (YoY)
151.07%483.48%18.53%-
EPS (Basic)
-1.06-3.26-17.24-16.65
EPS (Diluted)
-1.06-3.26-17.24-16.65
Shares Outstanding
23.2519.53--
Free Cash Flow
-19.21-21.84-21.63-17.79
Free Cash Flow Per Share
-0.91-2.61-15.07-14.70
EBITDA
-22.5-25.16-24.97-20.21
EBIT
-22.5-25.16-24.97-20.21
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q